January 13, 2020 6:38pm

Not as “newsy” as in the past; although Stemline Therapeutics (STML) reported $43.2 million in estimated ELZONRIS net revenues for FY2019

Preopen indications: 4 HITs <Sold into strength -EDIT (+$0.48), RARE (+$3.56), RGNX (-$0.93) and CLBS (-$0.18)> and 6 MISS <ALNY (-$4.60), FATE (-$0.25), BLUE (-$3.97), AXGN (-$1.76) CRSP (-$0.91) and NTLA (-$1.18)>

I make a commitment to provide need-to-know “facts in evidence” as equity’s volatility is one tactical signal for stocks.

 

The Dow closed UP +82.13 points (+0.28%), the S&P closed UP +22.78 points (+0.70%) and the NASDAQ closed UP +95.07points (+1.04%)

 

Henry’omics:

Indexes closed higher on Monday, resuming the rally that started last week amid news the U.S. will remove China from a list of currency manipulating countries, increasing optimism ahead of the signing of a key trade agreement.

Investors were looking ahead to the start of the J.P. Morgan healthcare conference and sector companies preparing to report earnings.

Expectations for the earnings season are low!

As I had stated, “JPMorgan will de-materialize many share pricings unless … there is NEWS of clinical results or an acquisition or two!”

 

Post the conference; institutions will be considering post presentations the bigger issue of risk tolerance as many investors hit the airways back from San Francisco and the ménage of conferences.

Low volume to the upside followed by high volatility to the downside as big names got hit hard!

 

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Monday the IBB closed down -1.29% while and XBI closed down -1.91%
  • Friday the IBB closed down -0.59% while and XBI closed down -0.99%

The advance/decline line scenario of 45 covered companies:

  • Monday the close was negative with an A/D line of 10/25, 1 flat of 36 covered,
  • Friday the close was negative with an A/D line of 16/19 , 1 flat of 36 covered,

 

Decliners:

  • uniQure NV (QURE -$5.59 after Friday’s -$0.08, Thursday’s +$1.46 and Wednesday’s-$0.45);
  • Alnylam Pharmaceuticals (ALNY -$4.60 after Friday’s +$1.19 and Thursday’s +$2.59);
  • bluebird bio (BLUE -$3.97);
  • Sage Therapeutics (SAGE -$2.47 after Friday’s +$1.12);
  • Global Blood Therapeutics (GBT -$2.17);

Incliners:

  • Ultragenyx (RARE +$3.56 after Friday’s +$10.23 and Thursday’s -$1.40);
  • Editas medicine (EDIT +$0.48);
  • Intrexon (XON +$0.28);
  • Athersys (ATHX +$0.08) – now there is a upside surprise;
  • Mesoblast (MESO +$0.07);

 

The percentage (%) indicators:

  • Monday’s range of the 10 upside was +0.02% (BOLD) to +6.60% (RARE) while the 25 downside ranged from -078% (SGMO) to -11.07% (AXGN); 
  • Friday’s range of the 26 upside was +0.10% (EDIT) to +10.23% (RARE) while the 19 downside ranged from -0.02% (BOLD) to -15.43% (AGTC); 

 

Upside volume stats:  to compare

  • Monday: 6 out of the 10 upside had higher than the 3 month average volume;
  • Friday: 12 out of the 16 upside had higher than the 3 month average volume;

Downside volume stats:

  • Monday: 11 out of the 25 downside had higher than the 3 month average volume;
  • Friday: 9 out of the 19 downside had higher than the 3 month average volume;

1 flat – BSTG

 

January’s sessions of 36 covered companies:

Monday closed NEGATIVE with 25 decliners, 10 advancers and 1 flat;

Friday closed NEGATIVE with 19 decliners, 16 advancers and 1 flat;

Thursday closed POSITIVE with 13 decliners, 22 advancers and 1 flat;

Wednesday closed POSITIVE with 11 decliners, 23 advancers and 2 flats;

Tuesday closed POSITIVE with 14 decliners, 22 advancers and 0 flat;

Monday closed POSITIVE with 14 decliners, 22 advancers and 0 flat;

Friday closed NEGATIVE with 20 decliners, 15 advancers and 1 flat;

Thursday closed NEGATIVE with 19 decliners, 15 advancers and 2 flats;

Wednesday markets were closed;

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.